Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 7/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | MTTP | P55157 | 7/20 | 0.47 |
| ▸ | APOB | P04114 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135115 | 1.00 | SMO (0.50) | SMOMYCRXRARXRBFABP4 | |
| Hydrochloric Acid SCHEMBL6200222 | 0.98 | SMO (0.49) | SMOMYCRXRARXRBFABP4 | |
| SCHEMBL4390271 | 0.86 | SMO (0.47) | SMOMTTPAPOB | |
| SCHEMBL4785732 | 0.86 | MYC (0.51) | MYCRXRARXRBFABP4KDM4E | |
| SCHEMBL6801907 | 0.85 | RXRA (0.51) | MYCRXRARXRBFABP4TAS2R14 | |
| SCHEMBL4203346 | 0.84 | MTTP (0.52) | SMOMTTPAPOB | |
| SCHEMBL28134400 | 0.84 | SMO (0.53) | SMOMTTPAPOBKDM4EALDH1A1 | |
| SCHEMBL6704877 | 0.83 | TTR (0.53) | RXRARXRBFABP4KDM4EALDH1A1 | |
| SCHEMBL10644876 | 0.82 | MRGPRX4 (0.49) | RXRARXRBFABP4TAS2R14KDM4E | |
| SCHEMBL4986456 | 0.82 | MYC (0.58) | MYCFABP4KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| EP-4058448-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | SMO 3834/4885MYC 4787/4885RXRA 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.